Defunct Company
Total Trials
15
As Lead Sponsor
As Collaborator
0
Total Enrollment
313
NCT01847222
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.
Phase: Phase 1
Role: Lead Sponsor
Start: May 31, 2013
Completion: Aug 31, 2014
NCT01848925
Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients
NCT02323685
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Phase: Phase 2
Start: Dec 31, 2014
Completion: Oct 31, 2016
NCT01374165
Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients
Phase: N/A
Start: Jan 31, 2015
Completion: Jan 31, 2015
NCT02437422
Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease
Start: Jun 5, 2015
Completion: Nov 18, 2015
NCT02490202
Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant
Phase: Phase 2/3
Start: Aug 31, 2015
NCT02533362
ANF-Rho in the Treatment of Chronic Neutropenia
Phase: Phase 1/2
Start: Oct 31, 2015
NCT02658162
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
Start: Feb 29, 2016
Completion: Dec 31, 2018
NCT02600390
SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer
Start: Mar 31, 2016
Completion: Nov 30, 2016
NCT02754999
A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.
Completion: May 17, 2017
NCT02672540
A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients
Start: Jul 31, 2016
Completion: May 31, 2017
NCT02411708
Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Start: Nov 30, 2016
Completion: Dec 31, 2017
NCT02950857
A Study of EPEG in Beta Thalassemia Patients
Start: Jun 28, 2017
Completion: Sep 27, 2017
NCT03559387
Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia
Start: Aug 3, 2017
Completion: May 22, 2018
NCT04677777
Safety Study of PP-007 in Subjects With Acute Ischemic Stroke
Start: Apr 24, 2024
Completion: Feb 28, 2025